Andrew Phillips
Director/Board Member at ENLIVEN THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Samuel Kintz | M | 38 |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
| Joseph Lyssikatos | M | 59 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
| Jorge da Silva | M | 47 |
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Anthony D. Piscopio | M | - |
OnKure, Inc.
 OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 13 years |
| Anish Patel | M | 43 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 5 years |
| Kristian Reich | M | 58 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Mallory Morales | F | 40 | 3 years | |
| Xuedong Liu | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 13 years |
| R. Carruthers | M | 66 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 5 years |
| Spike N. Loy | M | 43 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Andrew Hirsch | M | 53 | 4 years | |
| Daniel Timms | M | - |
BiVACOR, Inc.
 BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | 16 years |
| Michael O'Dwyer | M | - |
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 9 years |
| Catherine Moukheibir | F | 64 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Frank G. Haluska | M | 64 |
Kestrel Therapeutics, Inc.
 Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
| Anthony Killarney | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 9 years |
| Jake Bauer | M | 45 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
| Ramnik Xavier | M | 62 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Matthew D. Disney | M | - |
Expansion Therapeutics, Inc.
 Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
| Richard Heyman | M | 66 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
| Simon Sturge | M | 65 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Matthias Bodenstedt | M | 36 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Mika Derynck | M | 61 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 2 years |
| Kara Lassen | M | 45 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 2 years |
| Renato T. Skerlj | M | - |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 4 years |
| Rishi Gupta | M | 46 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | 1 years |
| Raymond Kelleher | M | 59 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA.
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX.
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 2 years |
| Scott Rocklage | M | 69 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | - |
| Oliver Daltrop | M | 47 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Michael Bookman | M | 37 | 3 years | |
| Arnout Ploos van Amstel | M | 60 |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Jorge Santos da Silva, Arnout Ploos van Amstel, and Kristian Reich. Jorge Santos da Silva has been the CEO since 2021. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | 3 years |
| Michael Kim | M | - |
Nexo Therapeutics, Inc.
 Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | - |
| Laurie Keating | F | 70 | 3 years | |
| Rhamy Zeid | M | - |
Nexo Therapeutics, Inc.
Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nexo Therapeutics is a small molecule oncology company that focuses on discovering and developing new drugs for cancer patients who do not have effective treatments. The company is based in Littleton, CO and Watertown, MA. The company uses covalent ligand discovery, chemical biology, cancer biology, and medicinal chemistry to target the underlying causes of cancer through innovative methods. Nexo Therapeutics was founded by John Athanosopoulos, Andrew J. Phillips, Michael Kim, and Rhamy Zeid. Andrew J. Phillips has been the CEO of the company since 2022. | - |
| Hugh O'Dowd | M | 59 |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 3 years |
| Nicholas A. Saccomano | M | 65 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | - |
| Jim Dillon | M | - |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | - |
| William Cohn | M | 64 |
BiVACOR, Inc.
BiVACOR, Inc. Medical SpecialtiesHealth Technology BiVACOR, Inc. develops and manufactures medical device. The firm specializes in rotary blood pumps, biomedical engineering. The company was founded by Daniel Timms in 2008 and is headquartered in Houston, TX. | 12 years |
| Christopher Nowers | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 4 years |
| Ann Berman | F | 71 | 3 years | |
| Allan Reine | M | 49 |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | 2 years |
| Gary Bridger | M | 61 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 2 years |
| Jolie Siegel | F | 48 | 4 years | |
| Benjamin Hohl | M | 35 | 1 years | |
| Lauren Zucker | F | 54 |
Yale University
| 13 years |
| Nicolas Mosimann | M | - | - | |
| Andrew Phillips | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
| Joao Neves | M | - | - | |
| Dragos Budinschi | M | - | - | |
| Nuala Brennan | F | 55 | 3 years | |
| Rohit Duggal | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
| William Kennard | M | 67 |
Yale University
| 10 years |
| Caleb Tripp | M | 38 |
Cormorant Asset Management LLC/Private Equity/
 Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 3 years |
| Helen Collins | M | 62 | 1 years | |
| Omar Khalil | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | 2 years |
| Isaac Manke | M | 47 |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 3 years |
| John DeMattei | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | - |
| Rahul Ballal | M | 46 | 1 years | |
| Peter Feinberg | M | 63 | 3 years | |
| Denis Patrick | M | - |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | - |
| Jaime Gerber | M | - |
Yale University
| 11 years |
| Steve Blum | M | 72 |
Yale University
| 13 years |
| George Schlich | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
| Guobao Zhao | M | - |
OnKure, Inc.
OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO. | 7 years |
| Eunan Maguire | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
| Stewart Fisher | M | 57 | 8 years | |
| Galya Blachman | M | 47 | - | |
| M. Isabel Chiu | M | - | 8 years | |
| Issac Manke | M | - |
ONK Therapeutics Ltd.
ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | - |
| Patrícia Isabel Sousa Caldinha | F | - | 2 years | |
| Laura Tadvalkar | F | - |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 3 years |
| Beth Seidenberg | M | 67 |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William McKee | M | 62 | 1 years | |
| Biren Amin | M | 51 | 1 years | |
| Jason S. Fisherman | M | 67 | - | |
| Jessamine Fitzpatrick | F | - |
Yale University
| 3 years |
| Grant Schafle | M | - |
Yale University
| 6 years |
| Michael Puempel | M | - |
Yale University
| 5 years |
| Xiao Bin Gao | M | - |
Yale University
| 4 years |
| Jay Scollins | M | 49 |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts. | 8 years |
| Eva Zlotnicka | F | 41 |
Yale University
| 2 years |
| Andrew Schwab | M | 53 | - | |
| Michael Gray | M | 53 | 4 years | |
| Jie Chen | M | 43 |
Yale University
| 7 years |
| Jane Jeong | F | - |
Yale University
| 4 years |
| Noah Siegel | M | - |
Yale University
| 4 years |
| Jianyu Yang | M | 53 |
Yale University
| 2 years |
| Denis Aven | M | - |
Yale University
| 4 years |
| Frederick Frank | M | - |
Yale University
| 4 years |
| Jenna Ciotti | F | - |
Yale University
| 4 years |
| Annie Creager | F | - |
Yale University
| 4 years |
| Li Cai | F | 40 |
Yale University
| 4 years |
| Melina Sanchez Montanes | F | - |
Yale University
| 5 years |
| Dave Sack | M | - |
Yale University
| 4 years |
| Wenping Zhou | M | - |
Yale University
| 7 years |
| Ryan Junwoo Lim | M | - |
Yale University
| 4 years |
| Levi Smith | M | - |
Yale University
| 6 years |
| Derek Brown | M | - |
Yale University
| 4 years |
| AIA Sarycheva | M | - |
Yale University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 75 | 75.76% |
| Switzerland | 15 | 15.15% |
| Ireland | 10 | 10.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Phillips
- Personal Network
